Vermillion to Present at the Canaccord Genuity 2017 Medical Technologies & Diagnostics Forum
AUSTIN, Texas, Nov. 6, 2017 /PRNewswire/ -- Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that Valerie Palmieri, President and Chief Executive Officer, will provide a corporate overview at the Canaccord Genuity 2017 Medical Technologies & Diagnostics Forum, being held at the Westin Grand Central Hotel in New York City on November 9, 2017.
Presentation Details | |
Date: | Thursday, November 9 |
Time: | 3:30pm Eastern Time |
Location: | Track 5 |
About Vermillion
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops and delivers innovative diagnostic and technology tools that help women with serious diseases. The company's initial in vitro diagnostic test, OVA1® (MIA), was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016, Vermillion received FDA clearance for Overa™, a second generation OVA1 (MIA2G) test with significantly improved specificity and ease of use. For additional information, including published clinical trials, visit www.vermillion.com.
Investor Relations Contact:
Michael Wood
LifeSci Advisors LLC
Tel 1-646-597-6983
mwood@lifesciadvisors.com
View original content with multimedia:http://www.prnewswire.com/news-releases/vermillion-to-present-at-the-canaccord-genuity-2017-medical-technologies--diagnostics-forum-300550241.html
SOURCE Vermillion, Inc.
